Sep. 30, 2015Products
"Ateos" Injector for "Trulicity" Type 2 Diabetes Treatment Wins "Good Design Award 2015" and Selected as One of Good "Design Best 100 2015"
About "Good Design Award"
The Good Design Award is one and only comprehensive design promotion system in Japan to commend good design works hosted by the Japan Institute for Design Promotion, a public interest incorporated foundation. For about 60 years since the launch of its predecessor, the Good Design Selection System (or G Mark System) in 1957, it has been operated as an initiative aimed at improving industries, life and culture in Japan through giving awards to outstanding design works. Applications come from a wide rage of design fields. Today, many businesses and organizations in and outside Japan submit applications. The G Mark, which is granted for use to award-winning design works, is well known as a symbol of good design. Among all the Good Design Award winners, 100 winners (Good Design Best 100) are selected as the candidates of the special award: those who received high evaluation as having capability to clear a path for tomorrow and signaling the future from such perspectives as advanced manufacturing in mature fields and exploration of the possibilities of design in growth fields.
Ateos® is a disposable injector to deliver a dose of prefilled drug solution, eliminating the need to prime. Patients do not need to prepare drug solution before use by themselves or titrate a single dose to be administered. Furthermore, since its needle is attached to the device beforehand, patients do not need to touch the needle directly and the needle is invisible during self-injection. Ateos® has been developed giving extra consideration not to evoke an image of pain at the injection site. To administer, patients remove the cap and place the bottom of Ateos® to the skin. Pressing the injection button will automatically deliver a dose subcutaneously. Once the delivery is completed, the needle automatically goes back inside the device. For more information on this award, visit http://www.g-mark.org/award/describe/42693?locale=en
About Eli Lilly and Company's diabetes business Eli Lilly and Company has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions -from medicines to support programs and more- to make lives better. For more information, visit www.lillydiabetes.com.
About Eli Lilly Japan
Eli Lilly Japan K.K. is a subsidiary of Eli Lilly and Company and celebrating the 40th anniversary of its foundation this year. It contributes to medical treatment in Japan through the, development, manufacture, import and sale of innovative pharmaceutical products that allow people to live longer, healthier, and more fulfilling lives. Lilly provides therapeutic agents for schizophrenia, depression, bipolar disorder, attention deficit disorder / hyperactivity disorder (AD/HD), cancer (non-small cell lung cancer, pancreatic cancer, biliary tract cancer, malignant pleural mesothelioma, urothelial carcinoma, breast cancer, ovarian cancer, malignant lymphoma and gastric cancer), diabetes mellitus, failure to thrive, osteoporosis, etc. Lilly is also developing diagnostic agents and therapeutic agents for Alzheimer-type dementia, rheumatoid arthritis, psoriasis, hypercholesterolemia, etc. For more detail, please visit our website. (URL:http://www.lilly.co.jp)
About Sumitomo Dainippon Pharma
Sumitomo Dainippon Pharma defines its corporate mission as "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide". By pouring all our efforts into the research and development of new drugs, we aim to provide innovative and effective pharmaceutical solutions to people not only in Japan but also around the world in order to realize our corporate mission. We have positioned Cardiovascular/Diabetes, Psychiatry & Neurology, and Speciality areas as our focus marketing areas in Japan. For more detail, please visit our website. (URL:https://www.ds-pharma.com)